Zacks Research Cuts Earnings Estimates for Globus Medical

Key Points

• Zacks Research lowered its Q4 2027 EPS estimate for Globus Medical to $1.35 from $1.37, while maintaining a “Strong Buy” rating. The broader full-year consensus estimate is $4.99 per share.
• Globus Medical recently reported adjusted EPS of $1.34, exceeding the $1.10 consensus estimate, while quarterly revenue of $789.6 million topped expectations and increased 5.9% year over year.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus rating and an average price target of $99.46 versus the stock’s $77.98 opening price. Institutional investors own approximately 95.2% of the company’s shares.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Investment analysts at Zacks Research decreased their Q4 2027 earnings per share (EPS) estimates for shares of Globus Medical in a report issued on Thursday, October 29th. Zacks Research analyst Team now expects that the medical device company will earn $1.35 per share for the quarter, down from their prior forecast of $1.37. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.99 per share.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. The company had revenue of $789.61 million for the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. Globus Medical's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

A number of other analysts have also recently commented on the stock. UBS Group assumed coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 price objective for the company. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a research note on Friday, September 18th. Stifel Nicolaus reduced their target price on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating on the stock in a report on Wednesday, July 8th. Truist Financial cut their target price on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating for the company in a research report on Thursday, July 16th. Finally, BMO Capital Markets initiated coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They set an "outperform" rating and a $94.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, Globus Medical currently has a consensus rating of "Moderate Buy" and an average price target of $99.46.

Globus Medical Price Performance

Globus Medical stock opened at $77.98 on Monday. Globus Medical has a 1-year low of $59.51 and a 1-year high of $101.40. The stock has a market cap of $10.47 billion, a price-to-earnings ratio of 19.94, a price-to-earnings-growth ratio of 1.26 and a beta of 0.96. The firm has a 50 day simple moving average of $77.64 and a 200-day simple moving average of $83.51.

Institutional Trading of Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its position in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock valued at $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Sculptor Capital LP raised its position in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company's stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company's stock valued at $152,474,000 after acquiring an additional 33,976 shares in the last quarter. Boston Trust Walden Corp raised its position in Globus Medical by 4.4% in the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company's stock worth $123,071,000 after purchasing an additional 69,782 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Globus Medical by 2.8% during the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company's stock worth $97,557,000 after purchasing an additional 30,412 shares during the period. Institutional investors and hedge funds own 95.16% of the company's stock.

Insider Activity

In other Globus Medical news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James Tobin sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company's stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 18.38% of the company's stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple periods, including Q3 2026 to $1.19, FY2026 to $4.98, FY2027 to $5.07, and FY2028 to $5.89. The firm also lifted estimates for Q1 2027, Q2 2027 and Q2 2028 by $0.01 each and maintained a “Strong-Buy” rating. The revisions suggest modestly improving expectations for Globus Medical’s earnings outlook. MarketBeat Globus Medical analyst estimates
• Positive Sentiment: Globus Medical was highlighted as a healthcare technology stock positioned for digital-health growth. Zacks cited projected 2026 earnings growth, an attractive valuation and innovation in essential medical services as reasons the company could benefit from broader healthcare technology adoption. Zacks healthcare technology stocks article
• Positive Sentiment: Another analysis called GMED undervalued even after a 77% run. This supports the view that analysts see additional upside based on Globus Medical’s earnings prospects and valuation, although the large prior gain may also encourage profit-taking. Globus Medical stock looks undervalued article
• Neutral Sentiment: The estimate increases were small—generally just $0.01 per share—and Zacks’ FY2026 estimate of $4.98 remains slightly below the broader consensus of $4.99. As a result, the revisions provide incremental support but may not be strong enough to overcome near-term selling pressure.
• Negative Sentiment: With GMED having already advanced substantially, investors may be locking in gains while waiting for a larger earnings or guidance catalyst. This profit-taking dynamic appears to be outweighing the otherwise favorable analyst commentary today.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.